Inflammasome components ASC and AIM2 modulate the acute phase of biomaterial implant-induced foreign body responses
Files
(Published version)
Date
2016
Authors
Christo, S.
Diener, K.
Manavis, J.
Grimbaldeston, M.
Bachhuka, A.
Vasilev, K.
Hayball, J.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Scientific Reports, 2016; 6(20635):20635-1-20635-14
Statement of Responsibility
Susan N. Christo, Kerrilyn R. Diener, Jim Manavis, Michele A. Grimbaldeston, Akash Bachhuka, Krasimir Vasilev & John D. Hayball
Conference Name
Abstract
Detailing the inflammatory mechanisms of biomaterial-implant induced foreign body responses (FBR) has implications for revealing targetable pathways that may reduce leukocyte activation and fibrotic encapsulation of the implant. We have adapted a model of poly(methylmethacrylate) (PMMA) bead injection to perform an assessment of the mechanistic role of the ASC-dependent inflammasome in this process. We first demonstrate that ASC(-/-) mice subjected to PMMA bead injections had reduced cell infiltration and altered collagen deposition, suggesting a role for the inflammasome in the FBR. We next investigated the NLRP3 and AIM2 sensors because of their known contributions in recognising damaged and apoptotic cells. We found that NLRP3 was dispensable for the fibrotic encapsulation; however AIM2 expression influenced leukocyte infiltration and controlled collagen deposition, suggesting a previously unexplored link between AIM2 and biomaterial-induced FBR.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/